Table 1 Baseline characteristics of treatment naive AML/MDS patients(n = 54).
Clinical Characteristics | Mean ± standard deviation or number |
|---|---|
Age (years) | 64.5 ± 8.1 |
Gender (male/female) | 31/23 |
Weight (kg) | 57.0 ± 10.2 |
Risk stratified (good/moderate/poor/unknown) | 6/13/28/7 |
Indication | |
 Acute myeloid leukemia | 50 |
 Myelodysplastic syndrome (MDS) | 4 |
Chemotherapy regimens | |
 Venetoclax and azacitidine (VA) | 31 |
 VA based chemotherapy | 7 |
 Venetoclax and other chemotherapeutic agents | 16 |
Comorbidity | |
 Neutropenia | 50 |
 Anemia | 47 |
 Thrombocytopenia | 46 |
 Pulmonary infection | 37 |
 Hypokalemia | 24 |
 Hypoproteinemia | 18 |
 Pleural effusion | 19 |
 Fungal Infection | 13 |
 Pericardial effusion | 10 |
 Liver Insufficiency | 9 |
 Gallbladder stones | 8 |
 Hyponatremia | 6 |
Combination of drugs | |
 Voriconazole | 16 |
 Posaconazole | 9 |
Response | |
 Complete remission | 28 |
 Partial remission | 12 |
 Non-remission | 14 |
Biochemical tests | |
 Platelet count (×109/L) | 62.86 ± 91.55 |
 Neutrophils (×109/L) | 0.42 ± 0.77 |
 White blood cell count (×109/L) | 1.59 ± 2.08 |
 Hemoglobin (g/L) | 68.28 ± 13.03 |
 Creatinine (μmol/L) | 68.72 ± 22.39 |
 Alanine aminotransferase (U/L) | 22.28 ± 17.21 |
 Aspartate Aminotransferase (U/L) | 24.64 ± 31.23 |
 Albumin (g/dL) | 33.73 ± 5.93 |
 Total bilirubin (mg/dL) | 19.15 ± 16.98 |
